Zobrazeno 1 - 5
of 5
pro vyhledávání: '"33"'
Autor:
Takashi Suzuki, Masato Kato, Genki Tanaka, Keiichi Kubota, Hidetsugu Yamagishi, Takatsugu Matsumoto, Johji Imura, Yuhki Sakuraoka, Takayuki Shimizu, Yukihiro Iso, Takayuki Shiraki, Taku Aoki, Takao Arakawa, Kyung Hwa Park, Kazuma Tago, Shozo Mori
Publikováno v:
Anticancer Research. 39:4315-4324
BACKGROUND/AIM This study aimed to obtain accurate differential diagnosis (DDx) of multicentric carcinogenesis (MC) and intrahepatic metastasis (IM) in recurrent lesions of hepatocellular carcinoma. MATERIALS AND METHODS A total of 79 patients who un
Autor:
Akihisa Matsuda, Satoshi Matsumoto, Kumiko Sekiguchi, Eriko Shinozuka, Hiroshi Yoshida, Hideyuki Suzuki, Nobuyuki Sakurazawa, Takeshi Yamada, Youichi Kawano
Publikováno v:
Anticancer Research. 39:4343-4350
Background/aim TAS-102 is recommended as salvage-line therapy for metastatic colorectal cancer (mCRC), but practical predictors for its efficacy are lacking. Patients and methods In a single-institutional retrospective study of 33 patients treated wi
Autor:
Azaz Ahmed, Niels Halama
Publikováno v:
Anticancer research. 40(11)
BACKGROUND/AIM The presence of TLS (tertiary lymphoid structures) is detectable in the microenvironment of human cancers and linked to better patient outcomes. The role of TLS in colorectal cancer liver metastases (CRCLM) is unclear. PATIENTS AND MET
Autor:
Florian Huemer, Richard Greil, Hanno Ulmer, Ewald Wöll, Lukas Weiss, Josef Thaler, Wolfgang Eisterer, Vera Trommet, Michael Hejna, Felix Keil, Birgit Gruenberger, Michael A. Fridrik
Publikováno v:
Anticancer Research. 37
Background/aim Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acq
Publikováno v:
Anticancer research. 37(8)
Background/aim The present study aimed to compare the utility of various inflammatory marker- and nutritional status-based prognostic factors, including many previous established prognostic factors, for predicting the prognosis of stage IV gastric ca